DON'T BUY
Could drop further. Trading at a high multiple.
BUY ON WEAKNESS
Expanding into new areas. Aging population is a plus. Earnings up 15/16%. Maybe a little above itself now.
WEAK BUY
Bullet proof portfolio-large caps (40%) Last 6 months has slowed to about 12% growth, but will eventually get back to the 30% range. Average down slowly.
WAIT
Bullet proof portfolio-mid caps (35%) A little bit pricey for its growth rate. Potential growth is huge.
DON'T BUY
Too high now. Have to get their earnings up to prove they can grow at 15%.
DON'T BUY
Too much competition and trades at too high a multiple.
BUY
Prefers over BNS because they have more diversified product base and a larger company. #1=TD, #2 = RY and #3 = CIBC
DON'T BUY
Need to get their act together.
DON'T BUY
Need to get their act together.
BUY
Likes, but prefers TD
DON'T BUY
Near term may have some growth. Too much debt.
BUY
Likes
HOLD
Good company, but will take some time for the earnings to catch up with the stock price.
BUY
20% earnings growth. Well diversified. A long term HOLD. Lots of cash. Good value now.
BUY
Bullet proof portfolio-small caps(25%) Good acquisitions. Into clinical trial studies which have good margins. 25% revenue growth and 65% earnings growth. DEBT/CASH FLOW ratio is less than 2.